Products
Platform
Research
Market
Learn
Partner
Support
IPO

B

Blue Jet Healthcare IPO

₹14,878 / 43 shares

Issue Date

--

Price Range

₹346

Lot Size

43

IPO Size

₹840.27 Cr

Blue Jet Healthcare IPO Listing Details

Listing On

1 Nov'23

Issue Price

--

Listed Price

₹ 380

Retail Gain/Listing Gain

9.83%

Schedule of Blue Jet Healthcare IPO

Start date

End date

Allotment of bids

Refund Initiation

Listing on exchange

01/11/2023

Tune in to know more about the company, IPO issue details, future strategies, important financial details, its presence and reach, service portfolio, and much more with Kinjal Parekh!
Blue Jet Healthcare IPO Review | Issue Details, Services and More

Kotak Securities

3m 07s

Blue Jet Healthcare Limited is a specialty pharmaceutical and healthcare ingredients and intermediates company, offering niche products targeted toward innovator pharmaceutical companies and multi-national generic pharmaceutical companies. The company has manufacturing capabilities in contrast media intermediates and high-intensity sweeteners, including saccharin and its salts.

The company’s operations are primarily organised into three product categories: (i) contrast media intermediates, (ii) high-intensity sweeteners, and (iii) pharma intermediates and active pharmaceutical ingredients (APIs).

In the past three Financial Years and the three months ended June 30, 2023, the company invoiced more than 400 customers in 39 countries. They have built a long-term customer base with innovator pharmaceutical companies and multi-national generic pharmaceutical companies, supported by committed multi-year contracts of up to five years.

With that, let's take a look at the competitive strengths and risk factors for Blue Jet Healthcare Limited:

  • The business is dependent on the sale of products to a limited number of key customers.
  • The business is dependent on Europe and the United States, which are regulated markets, for a significant portion of their revenue from operations.
  • If the company is not able to commercialise new products in a timely manner, the business, financial condition and prospects will be adversely affected.
  • Continue to integrate into more advanced intermediates for contrast media.
  • Build additional production capacity to keep in step with the envisaged increase in customer demands.
  • Focus on operational efficiency and mitigation of supply chain risks.
Loading chart...
Here's a video playlist to help you invest in Blue Jet Healthcare Limited IPO
How to apply for IPO through ASBA

Kotak Securities

00m 59s

How to apply for an IPO using UPI
Kotak Securities 01m 19s
Apply for Blue Jet Healthcare IPO